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Abstract 
Background: To compare efficacy of manual 
vacuum aspiration with sublingual misoprostol for 
the treatment of incomplete abortion in terms of 
frequency of blood loss and decreased haemoglobin. 
Methods: In this randomized controlled trial,   
patients with incomplete abortion, open cervical os, 
vaginal bleeding, history of vaginal bleeding during 
this pregnancy and uterine size of less than or equal 
to 12wks menstrual period were included.  
Consenting women were randomized to either 
Group A who received a single dose of 600 
microgram of sublingual misoprostol or Group B 
who underwent manual vacuum aspiration for 
evacuation of retained products of conception. Both 
groups comprised of 150 patients each. Pre and post 
(after 48 hours) treatment haemoglobin levels were 
measured. 
Results: Mean fall in haemoglobin level <1g/dl 
from baseline level was seen in misoprostol group 
while a mean fall of <0.5g/dl from baseline level was 
observed in MVA group (p<0.001, 95% CI, t=1.64, eta 
squared=0.006).  A significant association was found 
with haemoglobin level, parity and age, with 
p=0.001, p= 0.05, p=0.02 respectively 
Conclusion: The efficacy of manual vacuum 
aspiration (MVA) is indicated by lower level of 
blood loss (Hb<0.5g/dl from baseline) as compared 
to 600µg sublingual misoprostol. MVA is associated 
with less complications than misoprostol. 
Key Words: Manual vacuum aspiration, 
Misoprostol, Haemoglobin level, Gestational age 
 
Introduction 
First trimester incomplete abortion is an important 
contributing factor of maternal mortality and 
morbidity.1 2  It is estimated that 80% of abortions are 
associated with first trimester and there is reduction in 
abortion rate with increasing gestational age.3  
Pakistan is a developing country with limited 
resources in health sector. Pakistan has slow fertility 
rate decline as compared to other developing 
countries.4 According to a recent survey, 
approximately 2.2 million abortions occur in Pakistan, 
signifying an annual abortion rate of 50 per 1,000 
pregnancies.5 
Incomplete abortion in first trimester could be 
managed through medical and surgical interventions. 
Most common medical intervention used in Pakistan is 
misoprostol. This has been found to be safe, effective 
and acceptable among women who are not willing for 
invasive procedures.6 The most common surgical 
procedure is manual vacuum aspiration (MVA). The 
success rate of MVA is 91.5 to 100% but it is associated 
with complications like infections, uterine perforations 
and cervical lacerations.7 
Weeks et al. reported that misoprostol had less 
complications associated with incomplete abortion 
treatment as compared to MVA.8 Misoprostol group 
reported lower level of pain but greater amount of 
blood loss as compared to MVA group. Rates of 
acceptability were found to be similar in misoprostol 
and MVA group while satisfaction rate was 94.2% in 
misoprostol and 94.7% in manual vacuum aspiration.9 
Incomplete abortion is associated with various 
gynecological complications in Pakistan. Limited data 
is available regarding comparison of misoprostol and 
MVA efficacy in terms of blood loss during incomplete 
abortion.10 11 So it becomes very important to 
understand the efficacy of both treatments in order to  
develop guidelines regarding maternal health.  
 
Patients and Methods  
A randomized controlled trial (RCT) with 1:1 ratio was 
conducted in Department of Obstetrics and 
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Gynaecology Unit-I, Holy Family Hospital (HFH), 
Rawalpindi, from June 2013 to December 2013. A 
sample size of 300 patients was obtained through 
WHO calculator with 95% confidence interval, 5% 
level of significance and 80% power of study.  Patients 
with incomplete abortion, open cervical os, vaginal 
bleeding, history of vaginal bleeding during on-going  
pregnancy and uterine size of less than or equal to 12 
weeks menstrual period were included in study. 
Exclusion criteria were known allergy to misoprostol 
or other prostaglandins, contraindication to 
prostaglandin therapy (asthma, hypertension, 
glaucoma) and suspected ectopic pregnancy. Pelvic 
infection or sepsis, haemodynamically unstable 
patients, those with previous scar uterus, anaemia of 
<9G/dl, and history of surgical evacuation in previous 
miscarriages were also not included. Approval was 
taken from Institutional Research Forum / Ethics 
Committee of Rawalpindi Medical University. 
Consenting women were randomized to either Group 
A who received a single dose of 600 microgram of 
sublingual misoprostol or Group B who underwent 
MVA for evacuation of retained products of 
conception. Pre and post (after 48 hours) treatment 
haemoglobin levels were measured. An independent t-
test was performed to observe the results before and 
after intervention. Chi- square test was used to see the 
association between different variables. 
 
Results 
Both groups comprised of 150 patients each. In Group 
A (Misoprostol), mean age of patients was 27.82 years 
± 4.16 SD, mean parity 1.67 ± 1.44 SD and mean 
gestational age 11.08 weeks ± 2.37 SD. In Group B 
(MVA), mean age of patients was 27.15 years ± 4.82 
Standard Deviation (SD), mean parity 1.46 ± 1.47 SD 
and mean gestational age was 11.21 weeks ± 1.94 SD 
(Table 1). In Group A, 60 patients were in 20-30 year 
age group. In Group B, 60 patients were found in 20-30 
year age group and 60 in age group 31-40 years (Table 
1). Mean fall in haemoglobin level <1G/dl from 
baseline level was reported in misoprostol group while 
a mean fall of <0.5G/dl from baseline level was 
reported in MVA group(p<0.001, 95% CI, t=1.64, eta 
squared=0.006).  A significant association was found 
with haemoglobin level, parity, age with p=0.001,p= 
0.05, p=0.02 respectively (Table 2). In Group A, 
90(60%) patients had gestational age <11 weeks while 
60(40%) had gestational age >11 weeks. In group B, 
60(40%) patients had gestational age <11 weeks while 
90(60%) had gestational age >11 weeks. The 
association was found to be statistically insignificant 
((χ2=5.152, df=1, p=0.272). 
Table 1 : Age Distribution in both 
interventional groups 
Age 
distribution 
(Years)  
Group A (Subligual 
Misoprostol) 
 Group B(Manual 
vacuum aspiration) 
No  Percentage No Percentage  
20-30   60 40% 60 40% 
31-40   50 33% 60 40% 
>40   40 27% 30 20% 
Total  150 100% 150 100% 
Table 2: Associations between two 
interventional groups and independent 
variables 
Independent 
variables  
Group A 
(Misoprostol) 
(n=150) 
Group B  
(MVA)* 
(n=150) 
 
Chi 
square 
value 
Signi-
ficance  
Haemoglobin level χ2=8.39
0 
0.004 
<l g/dl  
from baseline 
83 (55%) 67(45%) 
>1g/dl  
from baseline  
67(45%) 83(55%) 
Parity χ2=18.2
75 
0.000 
1 99(66%) 51(34%) 
>1 51(34%) 99(66%) 
Age groups χ2=9.699 0.002 
20-30 years 60(40%) 60(40%) 
31-40 years 50(33%) 60(40%) 
>40 years 40(27%) 30(20%) 
*MVA= Manual Vacuum Aspiration 
 
Discussion 
First trimester miscarriage is one of one most common 
complications of pregnancy occurring in 10-15% of 
clinically recognized pregnancies.12 13 In present study 
a total of 300 patients underwent interventions with a 
ratio of 1:1 between both groups. Sochet et al. reported 
their mean age in misoprostol group was 28.1±7.2 SD 
while in MVA group mean age was 28.7±7.1SD.14 15In 
our study mean fall in hemoglobin level <1g/dl from 
baseline level was reported in misoprostol group while 
a mean fall of <0.5g/dl from baseline level was 
reported in MVA group. Sexana et al. reported that 
MVA group had shown lower side effects and higher 
pain scores as compared to misoprostol.14 16 Oral 
misoprostol was reported as more acceptable and well 
suited in limited resource health sectors. Women in 
misoprostol group were more willing to re use the 
method next time and were satisfied with the entire 
procedure.17 18 
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Fateen et al. and Madden et al reported that 
misoprostol group is associated with less 
complications as compared to MVA.10 19 Other studies 
have reported that for uncomplicated incomplete 
abortion in first trimester MVA and misoprostol are 
equally effective, safe and acceptable to the patients. 20 
21 Any procedure can be used according to the 
patient’s preference and available resources.22 23Hou et 
al. reported that mean change in hemoglobin level 
among patients of both groups MVA and misoprostol 
was similar (p<0.01). While heavy bleeding was rarely 
reported.24 Another study reported that 400µg 
sublingual misoprostol is more effective and safe in 
areas where surgical treatment is unavailable.25 
 
Conclusion 
• Efficacy of Manual vacuum aspiration (MVA) is 
indicated by lower level of blood loss (Hb<0.5g/dl 
from baseline) as compared to 600µg sublingual 
misoprostol.  
• MVA is associated with less complications than 
misoprostol. In developing countries like Pakistan 
where maternal mortality and morbidity is an 
important issue, MVA would be a safe and 
effective technique for uncomplicated abortion in 
first trimester.  
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